Paclitaxel oral - Hanmi Pharmaceutical

Drug Profile

Paclitaxel oral - Hanmi Pharmaceutical

Alternative Names: Oral paclitaxel - Hanmi Pharmaceutical; Oraxol; Paclitaxel/HM 30181A

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Athenex; Hanmi Pharmaceutical; PharmaEssentia Corporation; Zenith Technology Corporation
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Gastric cancer
  • Phase I Oesophageal cancer; Solid tumours

Most Recent Events

  • 24 Nov 2017 Phase-I development for Solid-tumours (Late-stage disease) in USA (PO, Capsule) (NCT01967043)
  • 24 Nov 2017 Phase-I development for Solid-tumours is ongoing in New Zealand (PO, Capsule) (ACTRN12614000365662)
  • 20 Nov 2017 Interim pharmacokinetics and adverse events data from a phase I trial in Cancer released by Athenex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top